Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

UTI AMC IPO Date, Review, Price Band, Form & Market Lot Details

By Jagat Joshi
October 27, 2019

UTI AMC IPO to hit the market on 29 September and closes on 1 October 2020. UTI AMC aka UTI Mutual Funds company is managing domestic mutual funds of UTI Mutual Funds, doing portfolio management, postal life insurance, retirement funds, offshore funds. UTI AMC has its headquarters in Mumbai, Maharashtra, and serving in India, Japan, Singapore, London, Dubai, and Bahrain. The company is promoted by LIC, BoB, PNB, SBI. UTI AMC subsidiaries are UTI Capital, UTI International Limited, UTI Ventures, and more. UTI Mutual Fund is the oldest and one of the largest mutual funds in India. They have over 10 million investor accounts under its 230 domestic schemes/plans as of September 30, 2017. Check out UTI AMC IPO date, price band, and market lot details.

Equity Shares outstanding prior to the Issue = 12,67,87,254 Shares
Employee Reservation of 2,00,000 Shares @500/- = Rs.10.00 Crores (after discount of ~54/-)
Offer for Sale of 3,87,87,081 Shares @554/- = Rs.2,148.8 Crores
Equity Shares outstanding after the Issue = 12,67,87,254 Shares

Category-wise Break up:
Anchor: 1,16,36,124 Shares = 644.64 Crores
QIB: 77,57,416 Shares = 429.76 Crores
NII: 58,18,062 Shares = 322.32 Crores
RII: 1,35,75,479 Shares = 752.08 Crores (Lot size: 27 = 5,02,796 Forms)
Empl. Quota: 2,00,000 Shares = 10.00 Crores (@500 per Share)
Total Issue: 3,89,87,081 Shares = 2158.80 Crores.

Subscription required for 1X
RII = 5,02,796 Forms
NII = 322.32 Crores

UTI AMC Company Profile

We are the seventh largest asset management company in India in terms of mutual fund QAAUM as of September 30, 2019, according to CRISIL. With more than 11 million Live Folios as of September 30, 2019, our client base accounts for 12.8% of the approximately 86 million folios that, according to CRISIL, are managed by the Indian mutual fund industry. Our history and track record in the mutual fund industry, strong brand recognition, distribution reach, performance and client relationships provide a platform for future growth.

We are a professionally managed company led by our Board of Directors and a dedicated and experienced management team. For purposes of the SEBI Mutual Fund Regulations, our four sponsors are the State Bank of India (“SBI”), Life Insurance Corporation of India (“LIC”), Punjab National Bank (“PNB”) and Bank of Baroda (“BOB”) (collectively, the “Sponsors”), each of which has the Government of India as a majority shareholder. T. Rowe Price Group, Inc., a global asset management company, is our other major shareholder (through its subsidiary T. Rowe Price International Ltd. (“TRP”))

We have a national footprint and offer our schemes through a diverse range of distribution channels. As of September 30, 2019, our distribution network includes 163 UTI Financial Centres (“UFCs”), 273 Business Development Associates (“BDAs”) and Chief Agents (“CAs”) (46 of whom operate Official Points of Acceptance (“OPAs”)) and 33 other OPAs, most of which are in each case located in B30 cities. Our IFAs channel includes approximately 51,000 Independent Financial Advisors (“IFAs”) as of September 30, 2019.

UTI AMC IPO Review:

Apply for Long Term Gain

Brokerage Firm IPO Review:

Anand Rathi: Subscribe for Long Term
Capital Market: Avoid
KR Choksey: Subscribe

UTI AMC IPO Dates & Price Band:

IPO Open:	29 September 2020
IPO Close:	01 October 2020
IPO Size:	Approx ₹2159 Crores (Approx)
Face Value:	₹10 Per Equity Share
Price Band:	₹550 – ₹554 Per Share
Listing on:	BSE & NSE
Retail Portion:	35%
Equity:	38,987,081 Shares
Discount:	₹54 / Employees

UTI AMC IPO Market Lot:

UTI AMC IPO Allotment & Listing:

Lot Size:	Minimum 27 Shares & Maximum 351 Shares
Minimum Amount:	₹14958
Maximum Amount:	₹194454

Basis of Allotment:	07 October 2020
Refunds:	08 October 2020
Credit to Demat Account:	09 October 2020
Listing Date:	12 October 2020

UTI AMC IPO Form:

How to apply the UTI AMC IPO? You can apply UTI AMC IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the UTI AMC IPO in the Invest section. The other option you can apply UTI AMC IPO via IPO forms download via NSE and BSE. Check out the UTI AMC forms – click NSE Forms & BSE Forms blank IPO forms download, fill and submit in your bank or with your broker.

UTI AMC Financial:

₹ in Crore
	Revenue	Expense	PAT
2017	1049	528	38
2018	1163	617	35
2019	1081	590	29
Q1 FY 2020	497	257	38

Company Promoters:

THE COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

Quick Links:

DRHP Draft Prospectus
RHP Draft Prospectus

UTI AMC IPO Registrar:

KFin Technologies Private Limited
(formerly known as “Karvy Fintech Private Limited”)
Selenium Tower-B, Plot 31 & 32, Gachibowli
Financial District, Nanakramguda, Serilingampally
Hyderabad 500 032, Telangana, India
Tel: +91 40 6716 2222
E-mail: utiamc.ipo@kfintech.com
Investor Grievance E-mail: einward.ris@kfintech.com
Website: www.kfintech.com
Contact Person: M Murali Krishna
SEBI Registration Number: INR000000221
Note: Check UTI AMC IPO allotment status on Karvy website allotment URL. Click Here

UTI AMC IPO Lead Managers:

Axis Capital Limited
BoA Merrill Lynch
Citigroup Global Markets India Private Limited
ICICI Securities Limited
JM Financial Consultants Private Limited
Kotak Mahindra Capital Company Limited
SBI Capital Markets Limited

Company Address:

UTI ASSET MANAGEMENT COMPANY LIMITED
UTI Tower, ‘Gn’ Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai 400051, Maharashtra
Tel: +91 22 6678 6666
Contact Person: Arvind Patkar
Company Secretary and Compliance Officer
E-mail: cs@uti.co.in
Website: https://www.utimf.com/
Corporate Identity Number: U65991MH2002PLC137867

UTI AMC IPO FAQs:

When UTI AMC IPO will open for Anchor Investors?

The Anchor Investors bidding to start on 28 September 2020.

When UTI AMC IPO will open for QIB, NII, and Retail?

The IPO to open on 29 September 2020 for QIB, NII, and Retail Investors.

What is UTI AMC IPO Investors Portion?

The investors’ portion for QIB-50%, NII-10%, and Retail-35%.

How to Apply the UTI AMC IPO?

You can apply UTI AMC IPO via ASBA online via your bank account. You can apply ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is UTI AMC IPO Allotment Date?

UTI AMC IPO allotment date is 07 October 2020. You can check IPO allotment here.

What is UTI AMC IPO Size?

Chemcon IPO size is Rs. 3000 crore.

What is UTI AMC IPO Listing Date?

UTI AMC IPO listing date is 12 October 2020. The IPO to list on NSE and BSE.

Note: The IPO price band and dates will be added as it will be officially announced. The IPO grey market premium (IPO GMP) will be added on the grey market page as it will start)

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.